Free
Meeting Abstracts  |   September 1997
Heparin-associated Thrombocytopenia and Thrombosis: Implications for Perioperative Management
Author Notes
  • (Slaughter) Assistant Professor, Department of Anesthesiology.
  • (Greenberg) Associate Professor, Departments of Medicine and Pathology.
  • Received from Duke University Medical Center and the Durham Veterans' Affairs Medical Center, Durham, North Carolina. Submitted for publication November 1, 1996. Accepted for publication February 4, 1997. Supported in part by National Institutes of Health grants HL03205 (to Dr. Slaughter) and HL28391 (to Dr. Greenberg).
  • Address reprint requests to Dr. Slaughter: Assistant Professor of Anesthesiology, Duke University Medical Center, Box 3094, Durham, North Carolina 27710. Address electronic mail to: slaug003@mc.duke.edu.
Article Information
Meeting Abstracts   |   September 1997
Heparin-associated Thrombocytopenia and Thrombosis: Implications for Perioperative Management
Anesthesiology 9 1997, Vol.87, 667-675. doi:
Anesthesiology 9 1997, Vol.87, 667-675. doi:
Key words: Thrombocytopenia, heparin-induced. Surgery, cardiac. Anticoagulation.
Since its discovery 80 yr ago, heparin has become a valuable component of medical therapeutics. [1] Lack of an alternative, rapidly acting, and reversible anticoagulant makes heparin one of the most widely prescribed pharmaceutical agents in hospitalized patients. Unfortunately, a subpopulation of patients exposed to heparin develop antibodies that induce thrombocytopenia and, almost paradoxically in some cases, thrombosis. [2] This clinical syndrome of immune complex-mediated thrombocytopenia, thrombosis, or both after heparin therapy comprises the condition of heparin-associated thrombocytopenia (HAT). Lack of standardized diagnostic criteria and limited availability of screening tests contribute to the misconception that HAT rarely occurs in patients having surgery. However, recent evidence suggests that heparin-associated antibodies are more prevalent than previously suspected and may even contribute to perioperative morbidity.
Historical Perspective
Although the anticoagulant activity of heparin was described initially in 1916, [1] it was not used clinically until the 1930s. [3] In 1941, descriptions of acute thrombocytopenia after heparin administration in laboratory animals [4] and humans [5] were published. The limited nature of this thrombocytopenic response appeared of little clinical importance. However, in 1958, Weisman and Tobin reported arterial embolism in 10 patients receiving heparin, and they first suggested that these cases represented a complication of "vigorous heparin therapy." [2] In 1964, Roberts et al. [6] described 11 patients with unexplained arterial embolization during heparin therapy and suggested that an antigen-antibody mechanism might play a role in these complications. This hypothesis was subsequently confirmed by Rhodes et al. [7] in 1973. Using complement fixation and aggregation absorption studies, these authors found a heparin-associated antibody in two patients experiencing HAT complicated by thrombosis.
Clinical Features
Heparin-associated thrombocytopenia typically develops 7-14 days after heparin therapy is initiated. However, in patients with previous exposure to heparin, signs may develop within 1 or 2 days. [8,9] Although thrombosis after heparin therapy has been reported in the absence of thrombocytopenia, in most cases these patients experienced a decrease in platelet count before the thrombotic event. [10,11] Although severe thrombocytopenia may develop in association with HAT, bleeding rarely occurs in patients who have not had surgery. [8] 
Heparin-associated thrombocytopenia is differentiated into two subtypes based on the severity of the thrombocytopenic response to heparin. [12,13] Patients with type I HAT experience a mild and usually asymptomatic thrombocytopenia during heparin therapy. In contrast, patients with type II HAT experience a more severe thrombocytopenia and are more likely to experience thrombotic complications. Unlike other drug-induced causes of platelet destruction, type II HAT typically resolves only after heparin is discontinued. Type I HAT often resolves despite continued exposure to heparin and may represent an exaggerated form of the normal acute platelet aggregatory response to heparin. [14,15] Whether the two subtypes of HAT represent independent pathophysiologic processes or merely variable responses to heparin-associated antibodies is unknown. Given the relatively benign course of type I HAT, the rest of this review will specifically focus on the pathophysiology, diagnosis, and management of type II HAT. Further, because categorization of patients into a particular subtype of HAT occurs only after retrospective examination of the patient's clinical course and because available diagnostic tests cannot differentiate subtypes of HAT, any patient who becomes thrombocytopenic during heparin therapy should be considered at risk for thrombosis.
In cases of heparin-associated thrombosis, HAT is frequently diagnosed only after the thrombotic event has occurred. These thromboses are most often arterial and involve major vessels of the extremities [6,16] and less frequently the cerebral [17,18] and mesenteric vasculature. [11] Thrombotic complications as a result of HAT have also been implicated in myocardial infarction, [19,20] skin necrosis, [21,22] and infarction of the kidney [23] and adrenal gland. [24,25] 
The role of HAT in venous thrombosis is less clearly established. Although recurrent venous thromboses and pulmonary emboli have been reported in patients with HAT, [20,23,26] whether these complications represent an adverse response to heparin or merely an extension of the preexisting thrombotic disorder for which heparin therapy was instituted is often difficult to discern.
Thromboses in patients with HAT frequently are extensive and involve multiple anatomic sites. [8,23,27] The incidence of thrombosis in HAT is unknown, but when it occurs, morbidity and mortality rates approach 80% and 30%, respectively. [8,11,28] As many as 20% of patients experiencing thrombosis of an extremity ultimately require amputation of the limb. [29-31] 
Incidence
Although recent evidence suggests the incidence of HAT after full-dose heparin therapy approximates 3%, previously published trials report incidence rates between 1.1% and 30%. [32-36] Lack of standard diagnostic criteria and limited sensitivity and specificity of diagnostic tests contribute to these widely varying estimates. Whether the incidence of HAT relates to the heparin dose is unknown, but limited exposure to heparin does not preclude development of this disease. Heparin-associated thrombocytopenia has been reported after low-dose subcutaneous heparin [37-39] and after exposure to heparin-containing arterial catheter flush solutions [40] and heparin-coated pulmonary artery catheters. [41] 
The type of heparin administered appears to influence the risk of HAT developing. Pooled estimates, based on recent prospective investigations, demonstrate a 2.9% incidence of HAT in patients exposed to bovine heparin compared with a 1.1% incidence in patients receiving porcine heparin. [36] The risk of HAT may be even lower in patients given low molecular weight heparin. In a recent investigation comparing prophylactic anticoagulant regimens for deep venous thrombosis after orthopedic surgery, Warkentin et al. [42] reported a 2.7% incidence of HAT in patients receiving prophylactic doses of unfractionated heparin and no cases of HAT in patients receiving low molecular weight heparin. Although isolated cases of HAT have been reported after treatment with low molecular weight heparins, in vitro and in vivo evidence suggests that low molecular weight heparins are less likely to induce thrombocytopenia and thrombosis. [43,44] 
Pathophysiologic Characteristics
The mechanism by which heparin causes thrombocytopenia is incompletely understood. Heparin-associated thrombocytopenia differs from other drug-induced thrombocytopenias in that platelets are activated before being cleared from the circulation. [45] Whether binding of immune complexes to the platelet surface or subsequent platelet activation is primarily responsible for premature clearance from the circulation is unknown. Intravenous gammaglobulin [46] and aspirin [12] attenuate the thrombocytopenic response to heparin, which suggests that both mechanisms play a contributory role. [47] 
The appearance of thrombocytopenia 7-14 days after heparin therapy suggests an immune-mediated mechanism for platelet destruction in HAT. Laboratory investigations further support this observation. Heparin-associated platelet aggregating factor appears in the immunoglobulin serum fraction. [7] Both Fc antibody fragments and monoclonal antibodies to the platelet Fc receptor inhibit heparin-associated platelet aggregation, which suggests that heparin, or more likely heparin-immune complexes, activate platelets by binding the platelet Fc receptor (Fc gamma RII). [48,49] Amiral et al. [50] showed recently that a complex of heparin and platelet factor 4 (PF4) is the antigenic target for heparin-associated antibodies. Platelet factor 4 is a heparin-binding protein found in plasma, stored in platelet alpha-granules, and released during platelet activation. [51,52] In most patients, heparin/PF4 complexes do not produce adverse sequelae. However, in patients with HAT, antibodies to the heparin/PF4 complex generate immune complexes that bind to platelet Fc gamma RII receptors, resulting in platelet activation. [53,54] 
The mechanism by which HAT is thought to initiate thrombosis is depicted in Figure 1. Warkentin et al. [55] found that serum and purified IgG from patients with HAT induce platelet activation and result in generation of procoagulant platelet-derived microparticles. These microparticles, which have been identified in the blood of patients with HAT, provide a phospholipid surface that accelerates formation of thrombin. [55-56] Thrombin generation, a major regulatory step in coagulation, contributes to further platelet activation and generation of fibrin clot.
Figure 1. Proposed mechanisms of thrombosis in HAT. Specific antibodies to the heparin/platelet factor 4 (PF4) complex generate immune complexes that bind to and activate platelets by way of Fc gamma RII receptors. Activated platelets release procoagulant microparticles, which provide a phospholipid surface to accelerate thrombin generation. In addition, heparin/PF4 immune complexes activate the extrinsic pathway of coagulation by binding to the vascular endothelial surface to induce localized expression of tissue factor.
Figure 1. Proposed mechanisms of thrombosis in HAT. Specific antibodies to the heparin/platelet factor 4 (PF4) complex generate immune complexes that bind to and activate platelets by way of Fc gamma RII receptors. Activated platelets release procoagulant microparticles, which provide a phospholipid surface to accelerate thrombin generation. In addition, heparin/PF4 immune complexes activate the extrinsic pathway of coagulation by binding to the vascular endothelial surface to induce localized expression of tissue factor.
Figure 1. Proposed mechanisms of thrombosis in HAT. Specific antibodies to the heparin/platelet factor 4 (PF4) complex generate immune complexes that bind to and activate platelets by way of Fc gamma RII receptors. Activated platelets release procoagulant microparticles, which provide a phospholipid surface to accelerate thrombin generation. In addition, heparin/PF4 immune complexes activate the extrinsic pathway of coagulation by binding to the vascular endothelial surface to induce localized expression of tissue factor.
×
Vascular endothelial injury may contribute to the pathogenesis of thrombosis in HAT. Endothelial cell binding sites for heparin have long been recognized. [57] More recently, IgG from the serum of patients with HAT was shown to bind to endothelial cells, promoting vascular endothelial expression of tissue factor, the primary mediator of plasma coagulation in vivo. [58] The vascular endothelial target for heparin-associated antibodies appears to be a complex of heparin, or a heparin-like molecule, and PF4. [54] Platelet factor 4 released during platelet activation and exceeding the binding capacity of plasma heparin presumably binds to heparin-like proteoglycans on the endothelial surface to provide a target for heparin-associated antibodies. [54] 
Clinical observations suggest that preexisting vascular endothelial damage may further potentiate thrombosis associated with HAT. Makhoul et al. [59] observed that 19 of 25 patients with HAT and an arterial or venous thrombotic complication experienced the thrombosis in a previously catheterized vessel. Patients having surgery who are by necessity subject to preoperative vascular catheterization and intraoperative trauma may be at particular risk for thrombosis associated with HAT.
Two additional clinical investigations showed an association of adverse postoperative outcome with HAT. In the first, the authors reviewed hospital records for patients with HAT who subsequently underwent vascular procedures requiring repeated exposure to heparin. [60] Three of four patients with HAT who were not receiving antiplatelet medication suffered major vascular thromboses after repeated exposure to heparin, compared with no thrombotic events in nine patients receiving antiplatelet medications before repeated exposure to heparin. In a subsequent investigation, 70 patients with HAT undergoing coronary artery bypass graft surgery in the absence of antiplatelet medication experienced a 44% incidence of thromboembolic complications and a 33% incidence of postoperative death. Preoperative identification of HAT and treatment with antiplatelet medication resulted in no thromboembolic complications or deaths. [61,62] Limitations of these investigations include their retrospective designs and the limited sensitivity and specificity of the platelet aggregation assay used to detect heparin-associated antibodies. No attempt was made preoperatively to screen patients for heparin-associated antibodies. Reliance on thrombocytopenia, thrombosis, or both to identify patients with HAT may have led the investigators to underestimate the prevalence of heparin-associated antibodies in this patient population. A recent report of a sensitive enzyme-linked immunosorbent assay for antibodies to the heparin/PF4 complex identified heparin-associated antibodies in 18% of patients screened before cardiac surgery. [63] The role of heparin-associated antibodies in postoperative outcome remains unclear. However, clinical and laboratory reports suggest that heparin-associated antibodies may contribute to postoperative complications and death, and this issue warrants further investigation.
Diagnostic Methods
Clinical investigation of HAT has been hampered by lack of sensitive and specific diagnostic tests. Currently available assays rely on detection of the activation or aggregation of donor platelets incubated with patient serum containing heparin-associated antibodies. The diagnostic "gold standard" has been the [sup 14 C]-serotonin release assay described by Sheridan et al. [64] This test is performed by incubating washed donor platelets containing [sup 14 C]-serotonin in the presence of the test patient's serum and both therapeutic and high concentrations of heparin. The presence of serotonin release at therapeutic, as opposed to high, concentrations of heparin indicates a positive test, which identifies the presence of heparin-associated antibodies. The serotonin release assay is effective in identifying HAT, with sensitivity and specificity rates of 99%. [65] Unfortunately, specialized skills needed to perform this assay limit its application to research settings.
Platelet aggregation studies that mix normal donor platelets and patient serum in the presence and absence of heparin represent the most widely used diagnostic assay for HAT. [66] Using carefully selected reactive donor platelets, sensitivity and specificity of aggregation studies approach 81% and 100%, respectively. [67] Chemiluminescent detection of adenosine triphosphate release after platelet activation may further increase the diagnostic sensitivity of platelet aggregation studies for heparin-associated antibodies. [68] A recently developed enzyme-linked immunosorbent assay to detect antibodies to the heparin/PF4 complex in plasma may be the most sensitive, specific, and widely applicable diagnostic test for HAT. [50,69] 
Because early diagnosis of HAT provides an opportunity to intervene and reduce the morbidity and mortality associated with this condition, any patient receiving heparin who subsequently develops thrombocytopenia or a thrombotic complication should be evaluated for the presence of heparin-associated antibodies. Some experts recommend that all patients receiving heparin should have platelet counts monitored at least twice each week. Laster et al. [70] demonstrated a 50% reduction in morbidity associated with HAT after introducing daily monitoring for thrombocytopenia during heparin therapy. Because thrombosis may occur early in the course of HAT before the nadir in platelet count, [8] any unexplained decrease in platelet count during heparin therapy should arouse the clinician's suspicion for the presence of heparin-associated antibodies. However, because diagnosis of HAT requires more than the presence of thrombocytopenia concurrent with heparin therapy, Chong [47] suggests that the diagnosis be based on four criteria: (1) thrombocytopenia during heparin therapy; (2) absence of other causes of thrombocytopenia; (3) resolution of thrombocytopenia after discontinuation of heparin; and (4) confirmation of a heparin-dependent platelet antibody by in vitro testing.
Anticoagulation of the Nonsurgical Patient with Heparin-associated Thrombocytopenia
The most essential step in treating any patient with HAT is immediate discontinuation of heparin. Various approaches are at least partially effective in preventing recurrent thrombosis and thrombocytopenia in these patients. Although substitution of warfarin for heparin provides protection, [71] most patients require interim anticoagulation during the 3-5 days needed to achieve an anticoagulant effect from warfarin. Antiplatelet agents such as aspirin and dipyridamole may offer some protection, but they have not proved entirely effective in preventing heparin-associated platelet aggregation. [11,59] 
The most successful approaches to anticoagulation of patients with HAT rely on use of a low molecular weight heparin or a heparinoid. Although 80-90% of low molecular weight heparins cross-react with antibodies responsible for HAT, these drugs have been safely administered to patients after first demonstrating the absence of platelet aggregation during in vitro screening of the patient's serum. [8,44] The heparinoid danaparoid sodium (Orgaran[trademark symbol]; Organon Inc., West Orange, NJ) appears to be the most promising treatment for thrombosis in patients with documented HAT. This anticoagulant consists of a mixture of polysulfated glycosaminoglycans-primarily heparan sulfate, dermatan sulfate, and chondroitin sulfate. [72] Because danaparoid cross-reacts with the heparin-associated antibody in only 10-20% of cases, this agent has been widely administered to provide anticoagulation in patients at risk for HAT and thrombosis. [73,74] 
Perioperative Management of the Patient with Heparin-associated Thrombocytopenia
The patient with HAT requiring anticoagulation for vascular or cardiac surgery presents a particular challenge for perioperative management. Although other anticoagulants have become available during the past decade, lack of a way to rapidly reverse activity of these drugs limits their application in the perioperative setting. No large-scale trials describe management of intraoperative anticoagulation for the patient with HAT. However, based on case reports and knowledge gained from treating the patient not having surgery who requires anticoagulation, we recommend an approach for perioperative management. Successful methods for providing perioperative anticoagulation in the patient with HAT follow one of three approaches: (1) delay surgery until the patient's plasma no longer induces platelet aggregation in the presence of heparin; (2) administer platelet inhibitors in addition to heparin; and (3) provide an alternative anticoagulant.
Because HAT has an immunologic basis, circulating antibody concentrations in most patients will decrease in time to a value at which an immediate thrombotic response to heparin is unlikely. Several reports describe successful application of this approach to the patient with HAT, [75] with the crucial proviso that the patient receive no additional heparin beyond intraoperative exposure. Anecdotally, additional heparin exposure from arterial catheter flush solutions [40] or heparin-coated pulmonary artery catheters [41] has resulted in recurrent thrombocytopenia and thrombosis. Further, preoperative in vitro testing must confirm that heparin-associated platelet aggregation is no longer present. Duration of a positive aggregatory response to a heparin challenge varies. Although the proaggregatory response may resolve in a few weeks, [75] heparin-induced platelet aggregation has been reported months after the initial episode of HAT. [76] Unfortunately, many patients requiring major vascular or cardiac surgery cannot postpone surgery for the period required to clear heparin-associated antibodies from the circulation.
Plasmapheresis may accelerate elimination of heparin-associated antibodies. Several reports in nonsurgical patients describe symptomatic resolution of HAT within several days of initiating plasmapheresis. [77,78] Although heparin-associated platelet aggregation also resolves, response of these patients to repeated heparin exposure is unknown. Further, plasmapheresis necessitates multiple exchange transfusions of fresh frozen plasma and the attendant risk of transfusion-transmitted diseases. [79] 
Several reports describe successful administration of heparin in the patient with HAT after treatment with platelet inhibiting drugs. Aspirin, dipyridamole, and the prostanoid inhibitor iloprost have each been effective in this setting. [59,60,80] Unfortunately, aspirin and dipyridamole do not inhibit platelet aggregation reliably in the presence of heparin-associated antibodies. Aspirin inhibited in vitro heparin-associated platelet aggregation in only 50% of patients with HAT. [11,59] Before re-exposing these patients to heparin, efficacy of aspirin or dipyridamole at inhibition of heparin-associated platelet aggregation should be confirmed in vitro. Iloprost also has partial efficacy-inhibiting platelet aggregation in HAT. Patients receiving a continuous infusion of iloprost have received normal doses of heparin for cardiac or vascular surgery without complication. However, vasoconstrictors frequently are necessary to counteract the vasodilating effects of iloprost. [80-82] 
Selecting an alternative anticoagulant to heparin appears to provide the safest approach to perioperative management of patients with HAT (Table 1). The heparinoid danaparoid has been particularly successful in this setting. [73,74] Although low molecular weight heparins may be considered, these drugs cross-react with heparin-associated antibodies in 80-90% of cases, thus limiting their applicability. [8] Because there is a small but definite risk of cross-reactivity between danaparoid and heparin-associated antibodies, preoperative in vitro testing must be performed to ensure compatibility in an individual patient. [83] Use of either a low molecular weight heparin or heparinoid complicates perioperative management of anticoagulation. Anticoagulant activity of these drugs is prolonged, and antagonists are currently unavailable. Further, because the major anticoagulant activity of these drugs occurs by inhibiting coagulation factor Xa, thrombin-based measures of anticoagulation such as the activated coagulation time and activated partial thromboplastin time are not useful for titrating the administration of these drugs. [73] Although several reports describe the use of danaparoid for cardiopulmonary bypass in the patient with HAT, lack of an effective neutralizing agent resulted in increased transfusion requirements in these patients. [73,74,84] 
Table 1. Alternative Anticoagulants for the Patient with Heparin-associated Antibodies
Image not available
Table 1. Alternative Anticoagulants for the Patient with Heparin-associated Antibodies
×
Clinical experience with anticoagulants other than the low molecular weight heparins and danaparoid in patients with HAT requiring surgery is limited. Ancrod, a fibrinogen-depleting enzyme derived from venom of the Malayan pit viper, has been administered successfully as an anticoagulant in nonsurgical patients who have HAT complicated by thrombosis. [85,86] In addition, cardiopulmonary bypass has been successfully performed using ancrod as an alternative to heparin, [87] and several reports describe use of this agent in patients with HAT requiring cardiopulmonary bypass. [88-90] Unfortunately, lack of an effective way to reverse anticoagulant activity of this agent results in increased postoperative bleeding. In addition, ancrod must be administered hours before surgery to achieve the desired reduction in fibrinogen concentration. As clinical applications of specific thrombin inhibitors become more widespread, these agents may provide additional alternatives for anticoagulation in the patient with HAT. Both hirudin [91,92] and argatroban [93] have been administered successfully in this setting. However, as with other currently available alternatives to heparin, intraoperative use of these drugs remains limited by their prolonged duration of action and the absence of effective neutralizing agents.
Despite recent improvements in diagnosis and management of HAT, many patients with this disease are identified only after a thrombotic complication. Until effective alternatives to heparin become more widely available, prevention of thrombotic complications of HAT must rely on minimizing heparin exposure and identifying high-risk patients before thrombosis occurs. Recent evidence suggests that patients having surgery may be at particular risk for thrombotic complications associated with this disorder. Although the incidence of HAT in patients having surgery remains unknown, this condition is undoubtedly more common than currently acknowledged and may represent a risk factor for adverse postoperative outcome. Further investigations are needed to define the incidence of HAT associated with surgery and the optimal approach to perioperative treatment of these patients.
The authors thank Jonathan B. Mark, M.D., and Andrew K. Hilton, M.D., for critically reviewing the manuscript.
REFERENCES
McLean J: The thromboplastic action of cephalin. Am J Physiol 1916; 41:250-7.
Weismann RE, Tobin RW: Arterial embolism occurring during systemic heparin therapy. Arch Surg 1958; 76:219-27.
Best CH: Preparation of heparin and its use in the first clinical cases. Circulation 1959; 19:79-86.
Copley AL, Robb TP: The effect of heparin on the platelet count in dogs and mice. Am J Physiol 1941; 133:P248.
Gollub S, Ulin AW: Heparin-induced thrombocytopenia in man. J Lab Clin Med 1962; 59:430-5.
Roberts B, Rosato FE, Rosato EF: Heparin-a cause of arterial emboli? Surgery 1964; 55:803-8.
Rhodes GR, Dixon RH, Silver D: Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet 1973; 136:409-16.
Warkentin TE, Kelton JG: Heparin-induced thrombocytopenia. Annu Rev Med 1989; 40:31-44.
Kapsch D, Silver D: Heparin induced thrombocytopenia with thrombosis and hemorrhage. Arch Surg 1981; 116:1423-7.
Phelan BK: Heparin-associated thrombosis without thrombocytopenia. Ann Intern Med 1983; 99:637-8.
Kappa JR, Fisher CA, Berkowitz HD, Cottrell ED, Addonizio VP Jr: Heparin-induced platelet activation in sixteen surgical patients: diagnosis and management. J Vasc Surg 1987; 5:101-9.
Green D: Heparin-induced thrombocytopenia (heparin supplement). Med J Aust 1986; 144:37-9.
Chong BH: Heparin-induced thrombocytopenia. Aust N Z J Med 1992; 22:145-52.
Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L: Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65:64-73.
Brace LD, Fareed J: An objective assessment of the interaction of heparin and its fractions with human platelets. Semin Thromb Hemost 1985; 11:190-8.
Baird RA, Convery FR: Arterial thromboembolism in patients receiving systemic heparin therapy. A complication associated with heparin-induced thrombocytopenia. J Bone Joint Surg 1977; 59A:1061-4.
Becker PS, Miller VT: Heparin-induced thrombocytopenia. Stroke 1989; 20:1449-59.
Ramirez-Lassepas M, Cipolle RJ, Rodvold KA, Seifert RD, Strand L, Taddeini L, Cusulos M: Heparin-induced thrombocytopenia in patients with cerebrovascular ischemic disease. Neurology 1984; 34:736-40.
Cummings JM, Mason TJ, Chomka EV, Pouget JM: Fibrinolytic therapy of acute myocardial infarction in the heparin thrombosis syndrome. Am Heart J 1986; 112:407-9.
Van Der Weyden MB, Hunt H, McGrath K, Fawcett T, Fitzmaurice A, Sawers RJ, Rosengarten DS: Delayed-onset heparin-induced thrombocytopenia. A potentially malignant syndrome. Med J Aust 1983; 2:132-5.
White PW, Sadd JR, Nensel RE: Thrombotic complications of heparin therapy. Including six cases of heparin-induced skin necrosis. Ann Surg 1979; 190:595-608.
Hartman AR, Hood RM, Anagnostopoulos CE: Phenomenon of heparin-induced thrombocytopenia associated with skin necrosis. J Vasc Surg 1988; 7:781-4.
Arthur CK, Isbister JP, Aspery EM: The heparin induced thrombosis-thrombocytopenia syndrome (H.I.T.T.S.): A review. Pathology 1985; 17:82-6.
Arthur CK, Grant SJB, Murray WK, Isbister JP, Stiel JN, Lauer CS: Heparin-associated acute adrenal insufficiency. Aust N Z J Med 1985; 15:454-5.
Findling JW, Korducki JM, Lahiri PK, Miller DD, Raff H: Bilateral adrenal hemorrhage associated with heparin-induced thrombocytopenia. Wisc Med J 1987; 86:27-9.
Battey PM, Salam M: Venous gangrene associated with heparin-induced thrombocytopenia. Surgery 1985; 97:618-20.
Blanke H, Lesch M, Strauer BE: Heparin-induced thrombocytopenia. Deutsche Medicinische Wochenschrift 1987; 12:96-9.
Silver D, Kapsch DN, Tsoi EK: Heparin associated thrombocytopenia, thrombosis and hemorrhage. Ann Surg 1983; 198:301-6.
Kelton JG: Heparin-induced thrombocytopenia. Haemostasis 1986; 16:173-86.
Towne JB, Bernhard VM, Hussey C, Garancis JC: White clot syndrome: peripheral vascular complications of heparin therapy. Arch Surg 1979; 114:372-7.
Ansell J, Deykin D: Heparin-induced thrombocytopenia and recurrent thromboembolism. Am J Hematol 1980; 8:325-32.
Eika C, Godal HC, Laake K, Hamborg T: Low incidence of thrombocytopenia during treatment with hog mucosa and beef lung heparin. Scand J Haematol 1980; 25:19-24.
Bell WR, Tomasulo PA, Alving BM, Duffy TP: Thrombocytopenia occurring during the administration of heparin. Ann Intern Med 1976; 85:155-60.
Bell WR, Royall RM: Heparin-associated thrombocytopenia: A comparison of three heparin preparations. N Engl J Med 1980; 303:902-7.
Powers PJ, Kelton JG, Carter CJ: Studies on the frequency of heparin-associated thrombocytopenia. Thromb Res 1984; 33:439-43.
Schmitt BP, Adelman B: Heparin-associated thrombocytopenia: A critical review and a pooled analysis. Am J Med Sci 1993; 305:208-15.
Johnson RA, Lazarus KH, Henry DH: Heparin-induced thrombocytopenia: A prospective study. Am J Hemat 1984; 17:349-53.
Hrushesky WJ: Subcutaneous heparin-induced thrombocytopenia. Arch Intern Med 1978; 138:1489-91.
Galle PC, Muss HB, McGrath K, Stuart JJ, Homesley HD: Thrombocytpenia in two patients treated with low-dose heparin. Obstet Gynecol 1978; 52(Suppl 1):9S-11S.
Heeger PS, Backstrom JT: Heparin flushes and thrombocytopenia. Ann Intern Med 1986; 105:143.
Laster J, Silver DS: Heparin-coated catheters and heparin-induced thrombocytopenia. J Vasc Surg 1988; 7:667-72.
Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-5.
Horellou MH, Conard J, Lecrubier C, Samama M, Roque-D'Orbcastel O, de Fenoyl O, Di Maria G, Bernadou A: Persistent heparin induced thrombocytopenia despite therapy with low-molecular-weight heparin. Thromb Haemost 1984; 51:134.
Leroy J, Leclerc MH, Delahousse B, Guerois C, Feloppe P, Gruel Y, Toulemonde F: Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (C2Y216). Semin Thromb Hemost 1985; 11:326-9.
Chong BH, Pitney WR, Castaldi PA: Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis and platelet aggregation. Lancet 1982; 2:1246-9.
Frame JN, Mulvey KP, Phares JC, Anderson MJ: Correction of severe heparin-associated thrombocytopenia with intravenous immunoglobulin. Ann Intern Med 1989; 111:946-7.
Chong BH: Heparin-induced thrombocytopenia. Br J Haematol 1995; 89:431-9.
Kelton JG, Sheridan D, Santos A, Smith J, Steeves K, Smith C, Brown C, Murphy WG: Heparin-induced thrombocytopenia: Laboratory studies. Blood 1988; 72:925-30.
Chong BH, Ismail F: The mechanism of heparin-induced platelet aggregation. Eur J Haematol 1989; 43:245-51.
Amiral J, Bridey F, Dreyfus M, Vissac AM, Fressinaud E, Wolf M, Meyer D: Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68:95-6.
Gruel Y, Boizard-Boval B, Wautier JL: Further evidence that alpha-granule components such as platelet factor 4 are involved in platelet-IgG-heparin interactions during Heparin-associated thrombocytopenia. Thromb Haemost 1993; 70:374-5.
Warkentin TE, Kelton JG: Heparin and platelets. Hemat Oncol Clin North Am 1990; 4:243-64.
Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt CM: Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994; 71:247-51.
Visentin GP, Ford SE, Scott JP, Aster RH: Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93:81-8.
Warkentin TE, Hayward CPM, Boshkov LK, Santos AV, Sheppard JI, Bode AP, Kelton JG: Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 11:3691-9.
Bode AP, Sandberg H, Dombrose FA, Lentz BR: Association of factor V activity with membranous vesicles released from human platelets: Requirement for platelet stimulation. Thromb Res 1985; 39:49-61.
Barzu T, Van Rijn JLML, Petitou M, Molho P, Tobelem G, Caen JP: Endothelial binding sites for heparin. Biochem J 1986; 238:847-54.
Cines DB, Tomaski A, Tannenbaum S: Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987; 316:581-9.
Makhoul RG, Greenberg CS, McCann RL: heparin-associated thrombocytopenia and thrombosis: A serious clinical problem and potential solution. J Vasc Surg 1986; 4:522-8.
Laster J, Elfrink R, Silver D: Reexposure to heparin of patients with heparin-associated antibodies. J Vasc Surg 1989; 9:677-82.
Walls JT, Curtis JJ, Silver D: Heparin-induced thrombocytopenia in patients who undergo open heart surgery. Surgery 1990; 108:686-93.
Walls JT, Curtis JJ, Silver D, Boley TM, Schmaltz RA, Nawara-wong W: Heparin-induced thrombocytopenia in open heart surgical patients: Sequelae of late recognition. Ann Thorac Surg 1992; 53:787-91.
Bauer TL, Arepalli G, Konkle BA, Mestichelli B, Shapiro SS, Cines DB, Poncz M, McNulty S, Edie RN, Mannion JD: Heparin-induced antibody formation and platelet activation in patients undergoing cardiopulmonary bypass surgery. Blood 1995; 86(Suppl 1):550a.
Sheridan D, Carter C, Kelton JG: A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67:27-30.
Chong BH, Castaldi PA: Heparin-induced thrombocytopenia. Blut 1989; 58:53-7.
Kelton JG, Sheridan D, Brain H, Powers PJ, Turpie AG, Carter CJ: Clinical usefulness of testing for a heparin-dependent platelet-aggregating factor in patients with suspected heparin-associated thrombocytopenia. J Lab Clin Med 1984; 103:606-12.
Chong BH, Burgess J, Ismail F: The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993; 69:344-50.
Stewart MW, Etches WS, Boshkov LK, Gordon PA: Heparin-induced thrombocytopenia: An improved method of detection based on lumi-aggregometry. Br J Haematol 1995; 91:173-7.
Amiral J, Bridey F, Wolf M, Boyer-Neuman C, Fressinaud E, Vissac AM, Peynaud-Debayle E, Dreyfus M, Meyer D: Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases. Thromb Haemost 1995; 73:21-8.
Laster J, Cikrit D, Walker N, Silver D: The heparin-induced thrombocytopenia syndrome: An update. Surgery 1987; 102:763-70.
Sobel M, Adelman B, Szentpetery S, Hoffman M, Posner MP, Jenvey W: Surgical management of heparin-associated thrombocytopenia. J Vasc Surg 1988; 8:395-401.
Stiekema JCJ, Wijnand HP, van Dinther THG, Moelker HCT, Dawes J, Vinchenzo A, Toeberich H: Safety and pharmokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers. Br J Clin Pharmacol 1989; 27:39-48.
Ortel TL, Gockerman JP, Califf RM: Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. Thromb Haemost 1992; 67:292-6.
Magnani HN: Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993; 70:554-61.
Olinger GN, Hussey CV, Olive JA, Malik MI: Cardiopulmonary bypass for patients with previously documented heparin-induced platelet aggregation. J Thorac Cardiovasc Surg 1984; 87:673-7.
Kapsch DN, Adelstein EH, Rhodes GR, Silver D: Heparin-induced thrombocytopenia, thrombosis, and hemorrhage. Surgery 1979; 86:148-55.
Nand S, Robinson JA: Plasmapheresis in the management of heparin-associated thrombocytopenia with thrombosis. Am J Hematol 1988; 28:204-6.
Brady J, Riccio JA, Yumen OH, Makary AZ, Greenwood SM: Plasmapheresis: A therapeutic option in the management of heparin-associated thrombocytopenia with thrombosis. Am J Clin Pathol 1991; 96:394-7.
Sloand EM, Pitt E, Klein HG: Safety of the blood supply. JAMA 1995; 274:1368-73.
Kappa JR, Fisher CA, Todd B, Stenach N, Bell P, Campbell F, Ellison N, Addonizio VP: Intraoperative management of patients with heparin-induced thrombocytopenia. Ann Thorac Surg 1990; 49:714-23.
Addonizio VP, Fisher CA, Kappa JR, Ellison N: Prevention of heparin-induced thrombocytopenia during open heart surgery with iloprost (ZK36374). Surgery 1987; 102:796-807.
Corbeau JJ, Jacob JP, Moreau X, Cottineau C, De Brux JL, Delhumeau A: Iloprost and extracorporeal circulation with conventional heparinization in a patient with heparin-induced thrombocytopenia. Annales Francais d'Anethesie et de Reanimation 1993; 12:55-9.
Chong BH, Ismail F, Cade J, Gallius AS, Gordon S, Chesterman CN: Heparin induced thrombocytopenia: Studies with a new low molecular weight heparinoid, Org 10172. Blood 1989; 73:1592-6.
Doherty DC, Ortel TL, DeBroijn N, Greenberg CS, Van Tright III P: "Heparin-free" cardiopulmonary bypass: First reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass. Anesthesiology 1990; 73:562-5.
Cole CW, Fournier LM, Bormanis J: Heparin-associated thrombocytopenia and thrombosis: optimal therapy with ancrod. Can J Surg 1990; 33:207-10.
Demers C, Ginsberg JS, Brill-Edwards P, Panju A, Warkentin T, Anderson DR: Rapid anticoagulation using ancrod in heparin induced thrombocytopenia. Blood 1991; 78:2194-7.
Zulys VJ, Teasdale SJ, Michel ER, Skala RA, Keating SE, Viger JR, Glynn MFX: Ancrod (Arvin) as an alternative to heparin anticoagulation for cardiopulmonary bypass. Anesthesiology 1989; 71:870-7.
Teasdale SJ, Zulys VJ, Mycyk T, Baird RJ, Glynn MFX: Ancrod anticoagutation for cardiopulmonary bypass in heparin-induced thrombocytopenia and thrombosis. Ann Thorac Surg 1989; 48:712-3.
Spiekermann BF, Lake CL, Rich GF, Humphries JE: Normal activated clotting time despite anticoagulation with ancrod in a patient with heparin-associated thrombocytopenia and thrombosis undergoing cardiopulmonary bypass. Anesthesiology 1994; 80:686-8.
O-Yurvati AH, Laub GW, Southgate TJ, McGrath LB: Heparinless cardiopulmonary bypass with ancrod. Ann Thorac Surg 1994; 57:1656-8.
Nand S: Hirudin therapy for heparin-associated thrombocytopenia and deep venous thrombosis. Am J Hematol 1993; 43:310-1.
Riess FC, Lower C, Seelig C, Bleese N, Kormann J, Muller-Berghaus G, Potzsch B: Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: successful for aortic valve replacement in man. J Thorac Cardiovasc Surg 1995; 110:265-7.
Matsuo T, Kario K, Chikahira Y, Nakao K, Yamada T: Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Br J Haematol 1992; 82:627-9.
Figure 1. Proposed mechanisms of thrombosis in HAT. Specific antibodies to the heparin/platelet factor 4 (PF4) complex generate immune complexes that bind to and activate platelets by way of Fc gamma RII receptors. Activated platelets release procoagulant microparticles, which provide a phospholipid surface to accelerate thrombin generation. In addition, heparin/PF4 immune complexes activate the extrinsic pathway of coagulation by binding to the vascular endothelial surface to induce localized expression of tissue factor.
Figure 1. Proposed mechanisms of thrombosis in HAT. Specific antibodies to the heparin/platelet factor 4 (PF4) complex generate immune complexes that bind to and activate platelets by way of Fc gamma RII receptors. Activated platelets release procoagulant microparticles, which provide a phospholipid surface to accelerate thrombin generation. In addition, heparin/PF4 immune complexes activate the extrinsic pathway of coagulation by binding to the vascular endothelial surface to induce localized expression of tissue factor.
Figure 1. Proposed mechanisms of thrombosis in HAT. Specific antibodies to the heparin/platelet factor 4 (PF4) complex generate immune complexes that bind to and activate platelets by way of Fc gamma RII receptors. Activated platelets release procoagulant microparticles, which provide a phospholipid surface to accelerate thrombin generation. In addition, heparin/PF4 immune complexes activate the extrinsic pathway of coagulation by binding to the vascular endothelial surface to induce localized expression of tissue factor.
×
Table 1. Alternative Anticoagulants for the Patient with Heparin-associated Antibodies
Image not available
Table 1. Alternative Anticoagulants for the Patient with Heparin-associated Antibodies
×